Nonmuscle invasive bladder cancer: a primer on immunotherapy

被引：14
|
作者：
Maruf, Mahir [1 ]
Brancato, Sam J. [1 ]
Agarwal, Piyush K. [1 ]
机构：
[1] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
来源：
CANCER BIOLOGY & MEDICINE | 2016年 / 13卷 / 02期
关键词：
BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; ADENOVIRAL RECEPTOR EXPRESSION; MYCOBACTERIUM-BOVIS; T-CELLS; CARCINOEMBRYONIC ANTIGEN; INTRAVESICAL TREATMENT; UROTHELIAL CARCINOMA; BCG IMMUNOTHERAPY; IMMUNE-RESPONSES;
D O I：
10.20892/j.issn.2095-3941.2016.0020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intravesical Bacillus Calmette-Guerin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeuticsin the treatment of nonmuscle invasive bladder cancer.
引用
收藏
页码：194 / 205
页数：12
相关论文
共 50 条
  • [1] Nonmuscle invasive bladder cancer: a primer on immunotherapy
    Mahir Maruf
    Sam J.Brancato
    Piyush K.Agarwal
    Cancer Biology & Medicine, 2016, 13 (02) : 194 - 205
  • [2] Nonmuscle invasive bladder cancer: a primer on immunotherapy
    Mahir Maruf
    Sam J.Brancato
    Piyush K.Agarwal
    Cancer Biology & Medicine, 2016, (02) : 194 - 205
  • [3] Intravesical immunotherapy in nonmuscle invasive bladder cancer
    Jokisch, Jan-Friedrich
    Karl, Alexander
    Stief, Christian
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 304 - 311
  • [4] Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments
    Gupta, Mohit
    Kates, Max
    Bivalacqua, Trinity J.
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 183 - 187
  • [5] Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer
    K. R. Begnini
    J. H. Buss
    T. Collares
    F. K. Seixas
    Applied Microbiology and Biotechnology, 2015, 99 : 3741 - 3754
  • [6] Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer
    Begnini, K. R.
    Buss, J. H.
    Collares, T.
    Seixas, F. K.
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2015, 99 (09) : 3741 - 3754
  • [7] Advances in nonmuscle invasive bladder cancer
    Konety, Badrinath R.
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 272 - 272
  • [8] Nonmuscle-invasive bladder cancer
    vom Dorp, F.
    Luemmen, G.
    Ruebben, H.
    UROLOGE, 2015, 54 (04): : 479 - 479
  • [9] Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer
    Hugar, Lee A.
    Gilbert, Scott M.
    Sexton, Wade J.
    Kamat, Ashish M.
    Li, Roger
    CURRENT OPINION IN UROLOGY, 2021, 31 (02) : 160 - 169
  • [10] Diagnostics techniques in nonmuscle invasive bladder cancer
    Soubra, Ayman
    Risk, Michael C.
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 283 - 288
12345